MediciNova, Inc. (MNOV)
1.76
+0.01
(+0.57%)
USD |
NASDAQ |
Sep 09, 14:39
MediciNova Profit Margin (Quarterly) : -504.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -504.8% |
| March 31, 2026 | -1.38K% |
| December 31, 2025 | -1.85K% |
| September 30, 2025 | -2.47K% |
| June 30, 2025 | -2.44K% |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | -72.31% |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | -9.54K% |
| June 30, 2021 | |
| March 31, 2021 | -4.70% |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -25.71% |
| Return on Assets | -23.77% |
| Return on Invested Capital | -25.59% |
| Gross Profit Margin (Quarterly) | 68.22% |
| Operating Margin (Quarterly) | -554.4% |
| Return on Net Operating Assets | -73.29% |